Conclusion Being a peptide involved in the regulation of food intake and energy metabolism, GLP-1 has been demonstrated to suppress food intake and reduce body weight
These downstream cascades persist beyond the peptide's plasma presence
By slowing gastric motility, bremelanotide is thought to reduce the oral absorption (bioavailability) of certain medications, such as naltrexone and indomethacin
Studies show up to 40% of weight lost on GLP-1 medications may come from lean body mass, including muscle
These data raise the possibility that supplementing glucagon-like peptide-1 receptor agonist treatment with GDF8 and activin A blockade could greatly improve the quality of weight loss during the treatment of obesity in humans
Liposomal vaccine delivery supports preclinical studies in immunotherapy, adjuvant optimization, and novel vaccine candidates